Formulary
Spesolimab: Indications, Dosing, Side Effects and Interactions
Spesolimab is a humanised recombinant monoclonal antibody that binds to interleukin-36R and blocks the activity of pro-inflammatory pathways.
MedNext Academy | 3 min read
Spesolimab: Indications, Dosing, Side Effects and Interactions
Spesolimab is a humanised recombinant monoclonal antibody that binds to interleukin-36R and blocks the activity of pro-inflammatory pathways.
Drug action
Spesolimab is a humanised recombinant monoclonal antibody that binds to interleukin-36R and blocks the activity of pro-inflammatory pathways.
Indications and dose
**Generalised pustular psoriasis (under expert supervision)**
- **Adult** (By Intravenous Infusion): 900 mg for 1 dose, if flare symptoms persist, consider a further 900 mg dose after 1 week.
Cautions
Chronic infection; history of recurrent infection Cautions, further information Immunisation Live vaccinations should be given at least 4 weeks before starting treatment, and should not be given during and for at least 16 weeks after treatment. M Tuberculosis Anti-tuberculosis therapy should be considered prior to initiating spesolimab treatment in patients with latent tuberculosis, a history of tuberculosis or possible previous exposure to tuberculosis in whom an adequate course of treatment cannot be confirmed. M
Contraindications
Clinically significant active infection
Side effects
Common or very common Fatigue; increased risk of infection; pruritus Frequency not known Peripheral neuropathy
Interactions
**Other interactions (2):**
- Live vaccines should not be given concurrently with spesolimab (see section 4.4).
- There is limited experience from the concomitant use of spesolimab with immunosuppressants in GPP patients (see section 4.4).
Pregnancy
Avoid (no information available). M
Breast feeding
Specialist sources indicate use with caution, especially if breast-feeding a neonate or pre-term infant (no information available). Large molecular weight suggests limited excretion into milk and drug molecule likely to be partially destroyed in the infant's gastro-intestinal tract. If treatment has occurred in early pregnancy, breast-feeding may be started immediately after birth. M
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Spesolimab in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

